linkedin

TERRA CARTA

Samsung Biologics was awarded the 2022 Terra Carta Seal, which recognizes global companies
driving innovation and action towards the creation of genuinely sustainable markets.

We are committed to sharing our sustainable progress and goals.
Learn more about our sustainability initiatives.

Driven.
For a Sustainable Life.

A blossom of hope

We are on a journey to help create a healthier adn sustainable future.

Our path to changing the world is never ending.

It touches everyone and everything.

Together we are

Driven. For a Sustainable Life.

Driven. For Life.

Samsung Biologics

Driven.
For a Sustainable Life.

Samsung Biologics aspires to lead the industry in protecting our planet for the health of future generations. In our mission to enrich human life while creating enduring and sustainable value, we are investing in practices and technologies to mitigate the risks of climate change in the greater areas we impact.

Net Zero Pathway

We are committed to achieving zero greenhouse gas (GHG) emissions and 100% renewable energy across our sites and supply chains by 2050. By engaging with our partners and suppliers to drive the transition to decarbonization, we aim to minimize our environmental impact and lay the foundation for sustainable growth.

2021

  • - Joined CDP
  • - Joined Frontier 1.5D
  • - Received ISO50001 Certification
    for Energy Management
  • - Joined SMI

2022

  • - Joined RE100
  • - Announced net zero goals
  • - Awarded Gold Sustainability
    Rating from EcoVadis

2030

Net Zero
· Operations 32% (RE30%)
· Supply Chain 35.2%

2050

Net Zero & 100% Renewable Energy
· Operation & Supply Chain

In Our Operations
Energy Reduction
  • - Improving energy efficiency
  • - Optimizing operational processes
Energy Substitution/Transition
  • - Substituting 100% of site energy consumption with renewables (RE100)
  • - Maximizing additional sources of renewable electricity through power purchase agreements (PPAs) and renewable energy certificates (RECs)
Across Our Value Chain
Supply Chain Emission
Management
  • - Engaging our suppliers to reduce
    their GHG emissions to achieve Net Zero
Others
  • - Minimizing the use of disposables in the manufacturing process through waste management and recycling
  • - Reducing overall water consumption and adopting water reuse practices
Site & Operations
  • Key Targets
    • ① (Reduction) Energy efficiency optimization
    • ② (Substitution) Solar Panel/Zero emission vehicles
    • ③ (Transition) Transition to renewables
  • Prioritize reduction and substitution to achieve a 32% emissions
    reduction and 30% renewable energy usage by 2030
Value Chain
  • Key Target
    • ① Initiatives with key suppliers to achieve Net Zero
  • Engaging in sustainable business initiatives to tackle other scope3 emissions such as waste and impact from business travel and commuting.
In Our Operations
Energy Reduction
  • - Improving energy efficiency
  • - Optimizing operational processes
Energy Substitution/Transition
  • - Substituting 100% of site energy consumption with renewables (RE100)
  • - Maximizing additional sources of renewable electricity through power purchase agreements (PPAs) and renewable energy certificates (RECs)
Site & Operations
  • Key Targets
    • ① (Reduction) Energy efficiency optimization
    • ② (Substitution) Solar Panel/Zero emission vehicles
    • ③ (Transition) Transition to renewables
  • Prioritize reduction and substitution to achieve a 32% emissions
    reduction and 30% renewable energy usage by 2030
Across Our Value Chain
Supply Chain Emission
Management
  • - Engaging our suppliers to reduce their GHG emissions to achieve Net Zero
Others
  • - Minimizing the use of disposables in the manufacturing process through waste management and recycling
  • - Reducing overall water consumption and adopting water reuse practices
Value Chain
  • Key Target
    • ① Initiatives with key suppliers to achieve Net Zero
  • Engaging in sustainable business initiatives to tackle other scope3 emissions such as waste and impact from business travel and commuting.

Global Initiatives

  • Engagement
  • Commitment/Initiative
The Sustainable Markets Initiative (SMI) was launched by His Majesty King Charles III, in his former role as His Royal Highness The Prince of Wales, at the World Economic Forum in 2020. It aims to lead the transition to a sustainable future by convening leaders to bring economic value into alignment with social and environmental sustainability.

As a proud supporter of the Terra Carta* mandate, we were also awarded the 2022 Terra Carta Seal, which recognizes global companies driving innovation and action towards the creation of genuinely sustainable markets.

Samsung Biologics joined together with health systems leaders from the public and private sector to formally launch the SMI Health Systems Taskforce at COP26 in Glasgow.

With its shared ambition to accelerate the delivery of net zero, sustainable healthcare to improve individual, societal and planetary health, the SMI Health Systems Taskforce is committed to delivering action in three priority areas:
Supply Chains
Championed by John Rim,
CEO Samsung Biologics
The Supply Chains Working Group is focused on accelerating the net zero transition across the health systems supply chains. The group aims to work with suppliers to decarbonize upstream product supply chains with a focus on renewable energy, clean heat, green transportation logistics and common supplier standards.
Patient Care Pathways
Championed by Paul Hudson,
CEO Sanofi
The Patient Care Pathways Working Group focuses on identifying opportunities to deliver net zero patient care while improving health and societal outcomes. The group aims to demonstrate how interventions across the care pathway can drive emissions reductions by decarbonizing care settings, preventing and managing disease progression, and delivering lower-CO2 solutions.
Digital Healthcare
Championed by Belén Garijo,
CEO Merck
The Digital Healthcare Working Group focuses on leveraging digital innovation and technology in order to drive the transition to net zero across health systems. The initial focus of the group is on demonstrating how digital solutions can support reducing emissions across clinical trials while improving patient outcomes and the patient experience.
SMI

The Sustainable Markets Initiative (SMI) was launched by His Majesty King Charles III, in his former role as His Royal Highness The Prince of Wales, at the World Economic Forum in 2020. It aims to lead the transition to a sustainable future by convening leaders to bring economic value into alignment with social and environmental sustainability.

As a proud supporter of the Terra Carta* mandate, we were also awarded the 2022 Terra Carta Seal, which recognizes global companies driving innovation and action towards the creation of genuinely sustainable markets.

Samsung Biologics joined together with health systems leaders from the public and private sector to formally launch the SMI Health Systems Taskforce at COP26 in Glasgow.

With its shared ambition to accelerate the delivery of net zero, sustainable healthcare to improve individual, societal and planetary health, the SMI Health Systems Taskforce is committed to delivering action in three priority areas:

Supply Chains (championed by John Rim, CEO Samsung Biologics).
The Supply Chains Working Group is focused on accelerating the net zero transition across the health systems supply chains. The group aims to work with suppliers to decarbonize upstream product supply chains with a focus on renewable energy, clean heat, green transportation logistics and common supplier standards.
Patient Care Pathways (championed by Paul Hudson, CEO Sanofi).
The Patient Care Pathways Working Group focuses on identifying opportunities to deliver net zero patient care while improving health and societal outcomes. The group aims to demonstrate how interventions across the care pathway can drive emissions reductions by decarbonizing care settings, preventing and managing disease progression, and delivering lower-CO2 solutions.
Digital Healthcare (championed by Belén Garijo, CEO Merck).
The Digital Healthcare Working Group focuses on leveraging digital innovation and technology in order to drive the transition to net zero across health systems. The initial focus of the group is on demonstrating how digital solutions can support reducing emissions across clinical trials while improving patient outcomes and the patient experience.

* The Terra Carta is a mandate that puts sustainability at the heart of the private sector. Its supporters are organizations formally recognized by the SMI to have confirmed their support of the Terra Carta to put Nature, People, and the Planet at the center of organizations’ value creation.

The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5°C above pre-industrial levels. Business leaders from Korea have joined with the British Embassy, Ewha Woman’s University, and Financial Supervisory Service to analyze the financial impact of climate response policies in the effort to address uncertainties associated with climate change and collectively thrive for a net-zero future.

As a business sector representative, Samsung Biologics will be providing data for each of its biopharmaceutical manufacturing plants through its Carbon Disclosure Project (CDP) initiative with Science Based Targets (SBT) to determine risks and opportunities on climate change as well as the financial impact.
Frontier 1.5D

The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5°C above pre-industrial levels. Business leaders from Korea have joined with the British Embassy, Ewha Woman’s University, and Financial Supervisory Service to analyze the financial impact of climate response policies in the effort to address uncertainties associated with climate change and collectively thrive for a net-zero future.

As a business sector representative, Samsung Biologics will be providing data for each of its biopharmaceutical manufacturing plants through its Carbon Disclosure Project (CDP) initiative with Science Based Targets (SBT) to determine risks and opportunities on climate change as well as the financial impact.

Renewable Electricity 100% (RE100) is a global initiative led by The Climate Group in partnership with the Carbon Disclosure Project (CDP) to bring together the world’s most influential businesses committed to 100% renewable power. Samsung Biologics joined RE100 in 2022 with a target to source 100% renewable electricity across its entire operations by 2050. To achieve its RE100 goal, Samsung Biologics plans to reduce energy consumption and transition to renewable energy by investing in solar panels, utilizing external energy resources, and converting its fleet to zero emission vehicles.
RE100

Renewable Electricity 100% (RE100) is a global initiative led by The Climate Group in partnership with the Carbon Disclosure Project (CDP) to bring together the world’s most influential businesses committed to 100% renewable power. Samsung Biologics joined RE100 in 2022 with a target to source 100% renewable electricity across its entire operations by 2050. To achieve its RE100 goal, Samsung Biologics plans to reduce energy consumption and transition to renewable energy by investing in solar panels, utilizing external energy resources, and converting its fleet to zero emission vehicles.

The Carbon Disclosure Project (CDP) is a not-for-profit charity that runs the global disclosure system for investors, companies and cities to manage their environment impact.

In its first year of disclosure in 2021, Samsung Biologics obtained ‘Management‘ level and also received the ‘Honor Award’ in the pharmaceutical sector from CDP Korea, making it the first and only biopharmaceutical company to be recognized for its continued efforts towards creating an eco-friendly management system.
CDP

The Carbon Disclosure Project (CDP) is a not-for-profit charity that runs the global disclosure system for investors, companies and cities to manage their environment impact.

In its first year of disclosure in 2021, Samsung Biologics obtained ‘Management‘ level and also received the ‘Honor Award’ in the pharmaceutical sector from CDP Korea, making it the first and only biopharmaceutical company to be recognized for its continued efforts towards creating an eco-friendly management system.

The TCFD (Task Force on Climate Related Financial Disclosures) develops recommendations on the types of information that companies should disclose to support their stakeholders.

Samsung Biologics has become a supporter of TCFD in July 2022, and released its first TCFD report in December. Through this report, we will transparently disclose yearly performance and activities, and increase effectiveness of business activity for climate change by receiving and reflecting various stakeholders’ opinion in our business operations.
TCFD

The TCFD (Task Force on Climate Related Financial Disclosures) develops recommendations on the types of information that companies should disclose to support their stakeholders.

Samsung Biologics has become a supporter of TCFD in July 2022, and released its first TCFD report in December. Through this report, we will transparently disclose yearly performance and activities, and increase effectiveness of business activity for climate change by receiving and reflecting various stakeholders’ opinion in our business operations.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION